Formulary restrictions may impact enrollment in pragmatic trials and limit generalizability of findings to vulnerable populations

on behalf of the PRIORITIZE HCV Study Group

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)729-731
Number of pages3
JournalClinical Trials
Issue number6
StatePublished - Dec 1 2020

ASJC Scopus subject areas

  • Pharmacology

Cite this